SCHEMBL5486789

SCHEMBL5486789

CC(=O)Nc1ccc(C2(c3ccc(NC(C)=O)cc3)C(=O)Nc3sc(Cl)cc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
MAPT P10636 3/20 0.40
NPC1 O15118 2/20 0.38
RAB9A P51151 1/20 0.38
ERCC1 P07992 1/20 0.38
ERCC4 Q92889 1/20 0.38
LRRK2 Q5S007 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
HTT P42858 1/20 0.37
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 1/20 0.36
CA12 O43570 1/20 0.36
BRD4 O60885 1/20 0.36
NR1I2 O75469 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
MB P02144 1/20 0.36
CYP1A1 P04798 1/20 0.36
CA3 P07451 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5480287 0.80 CHRM2 (0.49) SMN1; SMN2MAPTHTTMEN1KMT2A
SCHEMBL5478145 0.78 SMN1; SMN2 (0.60) SMN1; SMN2MAPTNPC1RAB9AL3MBTL1
SCHEMBL5478476 0.77 HTR6 (0.35) SMN1; SMN2MAPTHTTMEN1CYP3A4
SCHEMBL5482126 0.75 SMN1; SMN2 (0.56) SMN1; SMN2MAPTNPC1RAB9ALRRK2
SCHEMBL5488536 0.74 SMN1; SMN2 (0.55) SMN1; SMN2MAPTLRRK2HTTALDH1A1
SCHEMBL5478939 0.72 SMN1; SMN2 (0.56) SMN1; SMN2MAPTNPC1RAB9AL3MBTL1
SCHEMBL5483441 0.71 SMN1; SMN2 (0.52) SMN1; SMN2MAPTHTTALDH1A1MEN1
SCHEMBL5474337 0.70 SMN1; SMN2 (0.60) SMN1; SMN2MAPTNPC1RAB9AL3MBTL1
SCHEMBL5479179 0.70 SMN1; SMN2 (0.53) SMN1; SMN2MAPTNPC1RAB9AHTT
SCHEMBL5485863 0.69 HTT (0.67) SMN1; SMN2MAPTNPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 SMN1; SMN2 234/4885MAPT 1785/4885NPC1 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.